Opioid and Heroin Addiction: Effects, Withdrawal, and Treatment

What Opioid Use Disorder Is

Opioids work by binding to specific receptors in the brain and body — primarily the mu receptor, which is most responsible for the pain relief, sedation, and euphoria opioids produce, alongside delta and kappa receptors that shape the broader effect. With sustained use, the brain adapts to the constant presence of the drug, and opioid use disorder develops as a chronic, relapsing condition rather than a single event — one where stopping becomes progressively harder even when someone genuinely wants to stop, because the adaptation runs deeper than willpower reaches.

Opioid dependence carries a significant public health toll: worldwide, an estimated 15.6 million people use illicit opioids, and in the United States alone, hundreds of thousands of deaths have been linked to opioid overdose since 2000. The economic burden — healthcare costs, lost productivity, premature mortality — has been estimated at between 0.2% and 2.0% of affected countries' gross domestic product.

What Counts as an Opioid

The category covers heroin, prescription painkillers such as oxycodone, hydrocodone, and morphine, and synthetic opioids including fentanyl. They act on the same receptors, so dependence and withdrawal follow a broadly similar pattern — but potency and duration differ enormously, and that difference changes how both intoxication and detox are managed. Fentanyl in particular is roughly 100 times more potent than morphine, which is part of why its presence in the drug supply has reshaped the overdose landscape so significantly.

Most street heroin in the United States now contains fentanyl, frequently without the buyer's knowledge. Drug trafficking organizations mix fentanyl into heroin, counterfeit pills, and other substances because of its potency and low production cost — and because illicit fentanyl production has no quality control, the concentration in any given batch is essentially unpredictable. Federal analysis of seized counterfeit pills has found fentanyl content ranging from a fraction of a milligram to more than twice a lethal dose, with roughly 4 in 10 tested pills containing a potentially lethal amount.

Effects of Opioid Use Disorder

Beyond the risk of overdose, sustained opioid use carries a range of physical effects. Chronic use commonly causes persistent constipation and other gastrointestinal slowing, hormonal disruption affecting reproductive function, and in men, is associated with erectile dysfunction; in women, disturbances in menstrual cycles. For people who inject opioids, infectious disease risk rises considerably — screening studies have found hepatitis A, B, or C present in roughly 80% to 90% of people who inject drugs, and HIV prevalence among this population varies widely by region, reported as high as 60% in some areas and closer to 10% in others. Injection use also carries risk of serious bacterial infections, and snorting opioids is associated with damage to the nasal lining that can, over time, lead to perforation of the nasal septum. Depression and other mood disorders frequently co-occur with opioid use disorder, complicating both the clinical picture and the course of treatment.

Why Opioid Withdrawal Feels the Way It Does

The physical discomfort of opioid withdrawal traces back to a specific brain region: the locus coeruleus, a cluster of neurons at the base of the brain that plays a central role in the body's alertness and stress response. Opioids suppress activity in this region as part of their sedating effect; with sustained use, the locus coeruleus compensates by increasing its own baseline activity to counteract that suppression. When opioids are removed, that compensatory activity is left unopposed, producing a surge of noradrenergic signaling throughout the nervous system — which is what actually generates the anxiety, muscle aches, gastrointestinal distress, and autonomic symptoms (racing heart, sweating, elevated blood pressure) that define opioid withdrawal.

This is also why opioid withdrawal, while it can feel severe, isn't generally considered medically dangerous the way alcohol or benzodiazepine withdrawal can be — the underlying mechanism doesn't carry the same seizure or delirium risk, even though the subjective experience is intensely unpleasant.

The Withdrawal Timeline

Short-acting opioids such as heroin produce withdrawal that starts sooner and resolves sooner. Longer-acting opioids, including methadone, produce a slower, more drawn-out course in both onset and resolution.

• 6–12 hours after the last short-acting dose: anxiety, yawning, runny nose, sweating, and muscle aches typically begin.
• 24–72 hours: this window generally represents the peak — nausea, vomiting, diarrhea, cramping, chills, insomnia, and restlessness in the legs.
• 4–7 days: acute physical symptoms subside for most people.
• Weeks to months: low mood, poor sleep, low energy, and persistent cravings can continue well beyond the acute phase. This extended window is generally described as the period when relapse risk is highest, since the acute discomfort has passed but the underlying drive to use often hasn't.

What Supervised Detox Provides

Clinicians generally assess withdrawal severity using a standardized scale, most commonly the COWS (Clinical Opiate Withdrawal Scale), which scores eleven observed and reported symptoms to categorize withdrawal as mild, moderate, moderately severe, or severe. This scoring helps determine both the intensity of monitoring needed and, in some cases, the timing of medication.

Comfort medications are commonly used to ease specific symptoms during detox — anti-diarrheal and anti-nausea medications, and non-opioid options like clonidine or lofexidine (an alpha-2 adrenergic agonist approved specifically for managing opioid withdrawal) to blunt the noradrenergic surge described above. Buprenorphine is also frequently used to manage withdrawal directly, though timing matters: because it's a partial opioid agonist, giving it too soon after full agonist use can actually trigger or worsen withdrawal symptoms rather than relieve them, which is part of why the COWS assessment is used to time its introduction carefully.

Medication for Opioid Use Disorder

Buprenorphine, methadone, and naltrexone have more research evidence behind them than any other approach to treating opioid use disorder, and are generally described as the standard of care rather than one option among many. Buprenorphine is a partial opioid agonist — it activates opioid receptors enough to reduce cravings and withdrawal without producing the same intensity of euphoria as a full agonist, which gives it a notably safer profile. Methadone is a full opioid agonist, longer-acting and more tightly regulated, historically dispensed through specialized opioid treatment programs. Both reduce withdrawal and cravings without the highs and lows of illicit use, allowing someone to stabilize and function without the cycle of intoxication and withdrawal driving daily life. Naltrexone works differently — it's an opioid antagonist that blocks opioid effects entirely, and is started only after withdrawal is fully complete, since giving it too early can itself precipitate withdrawal.

Research consistently finds that people receiving one of these medications stay in treatment longer and have substantially lower mortality than those who don't, including specifically lower rates of fatal overdose. Regulatory changes in recent years have also expanded buprenorphine access considerably — providers with standard controlled-substance prescribing authority can now prescribe it for opioid use disorder without the additional waiver previously required, a change intended specifically to reduce barriers to this evidence-based treatment. Choice of medication and dosing remains a clinical decision made between a person and their prescriber, based on individual history and circumstances.

Overdose Risk After a Break in Use

Tolerance falls quickly during any break in opioid use — whether from detox, a hospital stay, incarceration, or any other period of abstinence. Returning to a previously routine dose after that tolerance has dropped is one of the most common circumstances associated with fatal opioid overdose, because the body is no longer able to handle an amount it previously tolerated without difficulty. This isn't a reason to avoid detox or treatment — it's the specific reason follow-up care and overdose preparedness are generally arranged before discharge rather than left to chance.

• Naloxone availability, along with someone nearby familiar with how to use it, is a standard harm-reduction measure wherever opioid use is a possibility.
• Overdose prevention hotlines exist specifically for situations where using entirely alone can't be avoided, so someone can check in during use and call for help if needed.
• Illicitly obtained substances — heroin, counterfeit pills, and others — may contain fentanyl without any indication on the outside, given how routinely it's mixed into the broader drug supply.
• Fentanyl test strips can detect the presence of fentanyl in a substance, though they don't measure how much is present, which limits how much safety they can guarantee on their own.

Treatment After Detox

Detox alone has a consistently poor track record for opioid use disorder when nothing structured follows it — detoxification addresses physical dependence, not the underlying disorder, and stopping there is strongly associated with returning to use. Residential treatment, intensive outpatient programs, and ongoing counseling — usually delivered alongside medication rather than instead of it — are associated with meaningfully better long-term outcomes. Contingency management, cognitive behavioral therapy, and family involvement each add measurable additional benefit on top of medication alone.

Why Residential Treatment Often Benefits Opioid Use Disorder Specifically

A few factors make residential care come up more often in discussions of opioid use disorder than for some other conditions. The clearest is the overdose-risk window described above. The period immediately following detox is when tolerance has dropped furthest and the risk of a fatal return to use is highest — and a residential setting keeps someone in a structured, substance-free environment through exactly that window, while medication for opioid use disorder is being started and titrated to an effective, stable level.

The contaminated drug supply adds another layer specific to opioids: because so much of the illicit supply now contains fentanyl at unpredictable concentrations, the margin for error in an unsupervised return to use has narrowed considerably compared to years past. A controlled environment during early treatment removes that specific risk during the highest-risk stretch. Co-occurring conditions are also common — infectious disease exposure from injection use, and mental health conditions like depression, both show up frequently alongside opioid use disorder. Residential programs that integrate medical and psychiatric care directly into the treatment team are positioned to address these alongside the substance use itself, rather than as separate concerns handled later or elsewhere. As with other substances, this doesn't mean residential treatment is the only appropriate setting — many people are treated effectively and safely in outpatient medication-based programs, particularly once past the highest-risk early window. But the specific combination of overdose risk, an unpredictable drug supply, and common co-occurring conditions gives the reasoning behind residential care for opioid use disorder a fairly concrete basis.

What Recovery Generally Looks Like

Opioid use disorder is generally described as a chronic, relapse-prone condition, similar in that respect to other chronic illnesses — but a highly treatable one, particularly with medication as part of the plan. People with a strong support system, consistent follow-up care, and engagement with medication for opioid use disorder are generally described as having a substantially better prognosis than those without these supports. The evidence on medication in particular is unusually consistent: across studies, staying on buprenorphine, methadone, or naltrexone is associated with longer retention in treatment and meaningfully lower mortality, making continued engagement with treatment — rather than any single moment of stopping use — the factor most closely tied to long-term outcomes.